Difference between revisions of "Palifermin (Kepivance)"
Jump to navigation
Jump to search
(Created page with "==General information== From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/palifermin NCI Drug Dictionary]: A recombinant form of the endogenous human...") |
m |
||
| (One intermediate revision by the same user not shown) | |||
| Line 8: | Line 8: | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
| + | [[Category:Keratinocyte growth factors]] | ||
[[Category:Chemotherapy protective agents]] | [[Category:Chemotherapy protective agents]] | ||
[[Category:Mucositis prevention]] | [[Category:Mucositis prevention]] | ||
| + | [[Category:Recombinant medications]] | ||
[[Category:FDA approved in 2004]] | [[Category:FDA approved in 2004]] | ||
Latest revision as of 14:33, 28 February 2024
General information
From the NCI Drug Dictionary: A recombinant form of the endogenous human keratinocyte growth factor. Palifermin binds to epithelial cell surface receptors in the lining of the mouth and gastrointestinal tract, resulting in stimulation of epithelial cell proliferation, differentiation and upregulation of cytoprotective mechanisms.
Also known as
- Generic name: rhKGF
- Brand name: Kepivance